Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India
· Delayed Price · Currency is INR 52.09
-0.60 (-1.14%)
May 9, 2025, 10:29 AM IST
Balaxi Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | - | 622.91 | 282.17 | 71.93 | 16.69 | 40.01 | Upgrade
|
| Short-Term Investments | - | 2.81 | 2.48 | 1.84 | - | - | Upgrade
|
| Cash & Short-Term Investments | 608.67 | 625.72 | 284.65 | 73.77 | 16.69 | 40.01 | Upgrade
|
| Cash Growth | 116.28% | 119.82% | 285.85% | 342.01% | -58.28% | 2908.05% | Upgrade
|
| Accounts Receivable | - | 557.05 | 522.82 | 275.59 | 767.59 | 297.14 | Upgrade
|
| Other Receivables | - | 12.95 | 10.73 | 18.48 | 6.05 | - | Upgrade
|
| Receivables | - | 589.01 | 550.02 | 311.84 | 774.12 | 299.09 | Upgrade
|
| Inventory | - | 821.68 | 1,050 | 987.04 | 136.18 | 8.32 | Upgrade
|
| Prepaid Expenses | - | 20.17 | 37.77 | 31.22 | 7.19 | - | Upgrade
|
| Other Current Assets | - | 45.14 | 12.44 | 6.16 | 3.53 | 1.19 | Upgrade
|
| Total Current Assets | - | 2,102 | 1,935 | 1,410 | 937.71 | 348.61 | Upgrade
|
| Property, Plant & Equipment | - | 170.87 | 190.16 | 60.27 | 11.67 | 1.87 | Upgrade
|
| Long-Term Investments | - | - | - | 44.7 | 34.16 | - | Upgrade
|
| Goodwill | - | 261 | 252.24 | 233.02 | 12.79 | - | Upgrade
|
| Other Long-Term Assets | - | 49.84 | 19.19 | 16.69 | 0.46 | 9.23 | Upgrade
|
| Total Assets | - | 2,583 | 2,397 | 1,765 | 996.8 | 359.71 | Upgrade
|
| Accounts Payable | - | 290.38 | 345.19 | 491.15 | 220.58 | 48.43 | Upgrade
|
| Accrued Expenses | - | 46.1 | 28.02 | 32.6 | 28.88 | 9.42 | Upgrade
|
| Short-Term Debt | - | 176.61 | 107.51 | 36.38 | 36.59 | - | Upgrade
|
| Current Income Taxes Payable | - | 28.83 | 50.57 | 72.52 | 60.12 | 24.17 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 0.63 | - | Upgrade
|
| Other Current Liabilities | - | 0.05 | 0.05 | 0.03 | 0.13 | 0.21 | Upgrade
|
| Total Current Liabilities | - | 541.97 | 531.33 | 632.68 | 346.93 | 82.22 | Upgrade
|
| Long-Term Debt | - | - | 8.7 | - | - | - | Upgrade
|
| Long-Term Leases | - | 17.43 | 16.86 | - | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | 9.95 | 11.01 | 0.39 | 0.07 | 0.03 | Upgrade
|
| Other Long-Term Liabilities | - | 0.43 | - | - | - | - | Upgrade
|
| Total Liabilities | - | 569.79 | 567.89 | 633.06 | 347 | 82.25 | Upgrade
|
| Common Stock | - | 108.98 | 101.81 | 100 | 100 | 100 | Upgrade
|
| Additional Paid-In Capital | - | 508.44 | 192.46 | 112.53 | 112.53 | 112.53 | Upgrade
|
| Retained Earnings | - | 1,358 | 1,432 | 919.11 | 437.27 | 64.93 | Upgrade
|
| Comprehensive Income & Other | - | 37.73 | 102.97 | - | - | - | Upgrade
|
| Shareholders' Equity | 2,159 | 2,014 | 1,829 | 1,132 | 649.8 | 277.46 | Upgrade
|
| Total Liabilities & Equity | - | 2,583 | 2,397 | 1,765 | 996.8 | 359.71 | Upgrade
|
| Total Debt | 321.02 | 194.04 | 133.07 | 36.38 | 36.59 | - | Upgrade
|
| Net Cash (Debt) | 287.65 | 431.68 | 151.58 | 37.39 | -19.9 | 40.01 | Upgrade
|
| Net Cash Growth | 205.71% | 184.78% | 305.40% | - | - | 2908.05% | Upgrade
|
| Net Cash Per Share | 5.27 | 8.39 | 2.99 | 0.75 | -0.40 | 1.06 | Upgrade
|
| Filing Date Shares Outstanding | 55.29 | 50.91 | 50.91 | 50 | 50 | 50 | Upgrade
|
| Total Common Shares Outstanding | 55.29 | 50.91 | 50.91 | 50 | 50 | 50 | Upgrade
|
| Working Capital | - | 1,560 | 1,404 | 777.36 | 590.78 | 266.39 | Upgrade
|
| Book Value Per Share | 39.51 | 39.56 | 35.92 | 22.63 | 13.00 | 5.55 | Upgrade
|
| Tangible Book Value | 1,896 | 1,753 | 1,577 | 898.62 | 637.01 | 277.46 | Upgrade
|
| Tangible Book Value Per Share | 34.71 | 34.43 | 30.97 | 17.97 | 12.74 | 5.55 | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.